DexCom 10-Q: Q3 Revenue $1.34B, Operating Income Up 35%, $1.0B Buyback Completed
DXCM sits 50% above its 52-week low of $54.11.
Summary
DexCom's Q3 10-Q shows revenue up 11% to $1.3445 billion with operating income up 35% to $327.2 million and 64% gross margin, while net income slipped 3% on a prior-year investment gain. The company completed its $1.0 billion 2026 buyback and authorized a new $1.0 billion program through 2027.
Key Events · Earnings and Guidance · DXCM
-
Q3 Revenue Grows 11% to $1.34B
Revenue of $1.3445 billion versus $1.2093 billion a year ago, with US revenue of $969.8 million and international $374.7 million.
-
Operating Income Jumps 35%
Operating income rose to $327.2 million from $242.5 million as gross margin reached 64% ($864.4 million gross profit, up 18%).
-
Net Income Dips on Prior-Year Gain
Net income fell 3% to $275.1 million because Q3 2025 included an $82.5 million gain on equity investments; diluted EPS was $0.72 versus $0.70.
-
$1.0B Buyback Completed, New Program Set
13.2 million shares repurchased for $1.0 billion in the nine months, including 4.6 million for $400.0 million in Q3 at an average $86.32; a new $1.0 billion program runs through December 31, 2027.
Analysis · DXCM · Industrial Applications And Services
The 8-K this afternoon gave the headline; the 10-Q fills in the quality of the quarter. Gross margin reached 64% ($864.4 million of gross profit on $1.3445 billion of revenue) and operating income rose 35% to $327.2 million, so the growth is coming with better manufacturing economics rather than just volume. Net income of $275.1 million was actually down 3% because last year's quarter included an $82.5 million gain on equity investments that did not repeat — the operating business improved even as the bottom line dipped. Cash generation remains strong at $1.12 billion from operations over nine months, and the company finished the $1.0 billion 2026 buyback (13.2 million shares, including 4.6 million in Q3 at an average $86.32), then authorized a fresh $1.0 billion program through December 2027. The offsets worth knowing: inventory reserves of $117.2 million year-to-date tied to winding down G6, and a securities class action dismissed with prejudice in August is now on appeal at the Ninth Circuit, with briefing due November 9 and December 9, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DXCM was trading at $81.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $54.11 to $92.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.